Cagrisema Sodium (10Mg)
Peptide Compound for Metabolic Research
Cagrisema is a co-formulation of cagrilintide and semaglutide, combining the effects of amylin and GLP-1 receptor agonism for enhanced weight loss and glycemic control.
Usage:
Used in research on obesity, appetite regulation, and glucose metabolism. Promising results in weight loss and Type 2 diabetes models.
Mechanism of Action:
Combines GLP-1 receptor activation with amylin receptor activity to suppress appetite, slow gastric emptying, and improve metabolic parameters.
Benefits:
- Appetite suppression
- Weight reduction
- Improved glucose control
- Delayed gastric emptying
Side Effects:
- Nausea
- Constipation
- Loss of appetite
- Mild gastrointestinal discomfort
Suggested Dosage:
Not specified
Half-life: 5–7 days (approximate)
Delivery: Subcutaneous injection